Achalasia  by Boeckxstaens, Guy E et al.
Seminar
www.thelancet.com   Vol 383   January 4, 2014 83
Achalasia
Guy E Boeckxstaens, Giovanni Zaninotto, Joel E Richter 
Achalasia is a rare motility disorder of the oesophagus characterised by loss of enteric neurons leading to absence of 
peristalsis and impaired relaxation of the lower oesophageal sphincter. Although its cause remains largely unknown, 
ganglionitis resulting from an aberrant immune response triggered by a viral infection has been proposed to underlie 
the loss of oesophageal neurons, particularly in genetically susceptible individuals. The subsequent stasis of ingested 
food not only leads to symptoms of dysphagia, regurgitation, chest pain, and weight loss, but also results in an 
increased risk of oesophageal carcinoma. At present, pneumatic dilatation and Heller myotomy combined with an 
anti-reﬂ ux procedure are the treatments of choice and have comparable success rates. Per-oral endoscopic myotomy 
has recently been introduced as a new minimally invasive treatment for achalasia, but there have not yet been any 
randomised clinical trials comparing this option with pneumatic dilatation and Heller myotomy.
Introduction
Achalasia is a motility disorder of the oesophagus that 
presents with symptoms of dysphagia, regurgitation 
of undigested food, respiratory symptoms (nocturnal 
cough, recurrent aspiration, and pneumonia), chest pain, 
and weight loss.1,2 Since its ﬁ rst description in 1674 by 
Sir Thomas Willis,3 spasm or failure to relax the lower 
oesophageal sphincter (LOS) has been identiﬁ ed as the 
cause of achalasia, resulting in impaired ﬂ ow of ingested 
food into the stomach and subsequent stasis of food and 
secretions in the oesophagus. Achalasia results from the 
disappearance of the myenteric neurons that coordinate 
oesophageal peristalsis and LOS relaxation.4 
The most common form of achalasia is idiopathic 
achalasia, which mostly occurs as sporadic cases. 
However, a similar clinical presentation can occur in 
patients with pseudoachalasia (2–4% of patients with 
suspected achalasia)5 or Chagas disease—diseases 
charac terised by degeneration of the myenteric plexus 
due to neoplastic inﬁ ltration6,7 or infection with 
Trypanosoma cruzi, respectively.8–10 Moreover, sporadic 
cases of paraneoplastic pseudoachalasia associated with 
anti-Hu antibodies have been reported, especially in 
patients with small-cell lung cancer.11 Although rare, 
achalasia can also be part of other complex syndromes 
such as Allgrove syndrome (also known as triple A 
syndrome—ie, alacrima, achalasia, adrenocorticotropic 
hormone deﬁ ciency), Down’s syndrome, or familial 
visceral neuropathy.12 In this Seminar, we mainly focus 
on the present insights and recent developments in the 
management of idiopathic achalasia. 
Epidemiology
Idiopathic achalasia is rare, with mean incidences of 
0·3–1·63 per 100 000 people per year in adults13–16 and 
0·18 per 100 000 people per year in children younger 
than 16 years.17 In adults, achalasia occurs with equal 
frequency in men and women14,15 and in white and non-
white people,18 but incidence increases with age. In most 
studies, the mean age at diagnosis was over 50 years.13,14,18 
Mean incidence in those aged over 80 years is 17 per 
100 000 people per year (95% CI 2–61).13 Mean prevalence 
was 8·7 per 100 000 people in a study from Iceland15 
whereas it was 10·8 per 100 000 people in a Canadian 
population-based study.14 In both studies, the prevalence 
increased over time whereas the incidence remained 
constant, most likely because achalasia is a chronic 
disorder with a low disease-related mortality rate. In an 
attempt to identify potential causative or environ mental 
factors, Farrukh and colleagues13 studied the epidemiology 
of achalasia in the immigrant south Asian population in 
Leicester (UK). Over 20 years, no changes in frequency 
of achalasia were reported, arguing against potential 
environmental factors as triggers of the disease. The 
ﬁ nding that autoimmune diseases such as type 1 dia-
betes mellitus, hypothyroidism, Sjögren’s syndrome, and 
uveitis are more prevalent in patients with achalasia than 
in the general population suggests that achalasia might 
have an autoimmune component.19
Pathophysiology
Immune-mediated ganglionitis
Oesophageal peristalsis and relaxation of the LOS are 
mediated and coordinated by myenteric neurons.4 In 
achalasia, these myenteric neurons are decreased in 
number or are absent, resulting in aperistalsis and 
impaired relaxation of the LOS. Most likely, the myenteric 
neurons disappear because of chronic ganglionitis. 
Detailed examination of resection specimens shows 
inﬁ ltration of cytotoxic lymphocytes expressing activation 
markers20–22 and evidence of complement activation 
within myenteric ganglia.23 In accordance, antibodies 
against myenteric neurons have been shown in serum 
samples of patients with achalasia,24,25 especially in those 
Lancet 2014; 383: 83–93
Published Online
July 17, 2013
http://dx.doi.org/10.1016/
S0140-6736(13)60651-0
Department of 
Gastroenterology, 
Translational Research Center 
for Gastrointestinal Disorders 
(TARGID), University Hospital 
Leuven, Catholic University of 
Leuven, Leuven, Belgium 
(Prof G E Boeckxstaens MD); 
Department of Surgical and 
Gastroenterological Sciences, 
University of Padova, UOC 
General Surgery, Sts Giovanni e 
Paolo Hospital, Venice, Italy 
(Prof G Zaninotto MD); and 
Division of Digestive Diseases 
and Nutrition, Joy McCann 
Culverhouse Center for 
Esophageal and Swallowing 
Disorders, University of South 
Florida Morsani College of 
Medicine, Tampa, FL, USA 
(Prof J E Richter MD)
Correspondence to:
Prof Guy E Boeckxstaens, 
Department of Gastroenterology, 
Translational Research Center for 
Gastrointestinal Disorders 
(TARGID), University Hospital 
Leuven, Catholic University of 
Leuven, Herestraat 49, 
3000 Leuven, Belgium
guy.boeckxstaens@med.
kuleuven.be
Search strategy and selection criteria
We searched PubMed and the Cochrane library with no date limits set for medical subject 
heading terms “achalasia”, “epidemiology”, “etiology”, “pathophysiology”, “genetics”, 
“diagnosis”, “manometry”, “radiology”, “symptoms”, “endoscopy”, “treatment”, 
“pharmacological”, “botulinum toxin”, “pneumodilation”, “myotomy”, “POEM”, “end-stage”, 
“dysplasia”, “carcinoma”, and “stem cells”. We did the last search in January, 2013. We 
reviewed all relevant articles published in English. For treatment strategy, we regarded 
randomised trials and meta-analyses as the most important study types. Where appropriate, 
we reviewed relevant abstracts presented at major gastrointestinal meetings.
Seminar
84 www.thelancet.com   Vol 383   January 4, 2014
with HLA DQA1*0103 and DQB1*0603 alleles.26 Because 
HLA proteins are crucial for antigen recognition, these 
ﬁ ndings suggest the involvement of an aberrant immune 
response to so far unknown antigens. Viruses, such as 
herpes simplex virus 1 (HSV-1), measles, and human 
papillomavirus have been proposed as potential antigens. 
HSV-1 DNA has been identiﬁ ed in oesophageal tissue, 
and evidence suggests that isolated oesophageal T cells 
are oligoclonal in nature in achalasia and speciﬁ cally 
proliferate and release cytokines on exposure of HSV-1 
antigens.27,28 Because HSV-1 is a neurotropic virus with a 
predilection for squamous epithelium, this hypothesis 
would ﬁ t with the selective loss of enteric neurons in the 
oesophagus. However, HSV-1 DNA was as frequently 
identiﬁ ed in the oesophagus of control individuals,28 
suggesting that HSV-1 only triggers persistent immune 
activation with subsequent loss of enteric neurons in 
genetically susceptible individuals (ﬁ gure 1).29 However, 
other investigators have not found HSV-1 or other viruses 
such as measles or human papillomavirus in oesophageal 
resection specimens from patients with achalasia.22,30,31
Genetics
Candidate gene studies, albeit in a small number of 
patients, have identiﬁ ed an association between achalasia 
and gene polymorphisms in HLA class II molecules,32–34 
vasoactive intestinal peptide receptor 1,35 KIT,36 inter-
leukin 10 promoter,37 and interleukin 23 receptor.38 
Moreover, familial achalasia has been reported, albeit 
rarely, further supporting a role for genetic factors in the 
pathogenesis of achalasia.12 An ongoing genome-wide 
association study will hopefully yield more clarity 
regarding this topic.
Diagnosis
Symptomatology
The most frequently occurring symptoms of achalasia 
are dysphagia (>90%) for solids and liquids, regurgitation 
of undigested food (76–91%), respiratory complications 
(nocturnal cough [30%] and aspiration [8%]), chest 
pain (25–64%), heartburn (18–52%), and weight loss 
(35–91%).1,39–41 Heartburn can lead to an erroneous diag-
nosis of gastro-oesophageal reﬂ ux disease, which might 
culminate in antireﬂ ux surgery. Nocturnal coughing 
mainly occurs in patients with substantial stasis of large 
amounts of food and secretions. Chest pain is pre-
dominantly present in patients with type III disease (see 
later)42 and responds less well to treatment than do 
dysphagia and regurgitation, which probably explains the 
less favourable therapeutic results obtained in patients 
with type III disease compared with those with type I 
or II disease.40,42 However, symptoms of achalasia are not 
speciﬁ c, which explains the long delay between onset of 
symptoms and the ﬁ nal diagnosis (up to 5 years in some 
studies).43,44 Although some patients lose a lot of weight 
(more than 20 kg),1 achalasia should also be considered 
in obese patients.
Radiology and endoscopy 
The ﬁ rst diagnostic step is to rule out anatomical lesions, 
neoplasia, or pseudoachalasia using endoscopy or 
radiology. Pseudoachalasia should particularly be sus-
pected in cases of rapidly progressing dysphagia, 
signiﬁ cant weight loss, and old age,6 and should be 
excluded by endoscopic ultrasound or CT scan. These 
investigations will reveal unusual thickening of the 
oesophageal wall, mass lesions, or even an inﬁ ltrating 
pancreatic carcinoma.7
Initial insult: viral, toxin?
Chronic infection Aberrant autoimmune 
response
Achalasia
Cytotoxic T cells
Autoimmune antibodies
Ganglionitis or loss 
of neurons
Immunogenetics:
HLA DQA1*0103 or
HLA DQB1*0603 
Figure 1: Present hypothesis proposing virus-induced 
autoimmune-mediated ganglionitis in achalasia
Insert shows inﬁ ltration of myenteric ganglion with T cells. Arrow shows 
myenteric nerves and ganglion cells. Reproduced with permission from 
Goldblum and colleagues.21
A B
Figure 2: Achalasia ﬁ ndings on radiological examination
(A) Typical bird-beak appearance in early achalasia. (B) Sigmoid-like appearance of decompensated oesophagus. 
Modiﬁ ed from Moonen and Boeckxstaens47 and Triadaﬁ lopoulos and colleagues,48 respectively, with permission.
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Especially in the early stage of achalasia, both endoscopy 
and radiology are less sensitive than manometry and only 
identify about half (or even less) of patients with early-
stage achalasia.41,45,46 In advanced cases, endoscopy might 
reveal a dilated oesophagus with retained food and 
increased resistance at the gastro-oesophageal junction. 
Radiological examination often shows a typical bird-beak 
image at the junction (ﬁ gure 2), with a dilated oesophageal 
body, sometimes with an air–ﬂ uid level and absence of an 
intragastric air bubble. In more advanced achalasia, 
severe dilatation with stasis of food and a sigmoid-like 
appearance can occur. Although radiology is not as 
sensitive as manometry, this investigation remains 
important to rule out structural abnormalities, estimate 
the diameter of the oesophagus, and assess the presence 
of epiphrenic diverticula.48 To assess emptying of the 
oesophagus, a timed barium swallow can be done, in 
which the height of the barium column 5 min after 
ingestion of diluted barium is a measure of emptying.49,50
Manometry 
On conventional manometry, absence of peristalsis, 
sometimes with increased intraoesophageal pressure 
owing to stasis of food and saliva, and incomplete 
relaxation of the LOS on deglutition (residual pressure 
>10 mm Hg) are the hallmarks of achalasia.2 Additionally, 
the resting tone of the LOS is often raised. High-resolution 
manometry (HRM) is increasingly being used to provide 
more detailed information on oesophageal motility.51 By 
means of catheters incorporating 36 or more pressure 
sensors spaced only 1 cm apart, HRM allows detailed 
pressure recording from the pharynx to the stomach and 
is regarded as the gold standard for diagnosis of achalasia.52 
The use of HRM has led to the subclassiﬁ cation of 
achalasia into three clinically relevant groups on the basis 
of the pattern of contractility in the oesophageal body:53 
type I (classical achalasia; no evidence of pressurisation), 
type II (achalasia with compression or compart mental-
isation in the distal oesophagus >30 mm Hg), and type III 
(two or more spastic contractions; ﬁ gure 3). Additionally, a 
new parameter to quantify LOS relaxation has been 
introduced: integrated relaxation pressure,55 which calcu-
lates the mean post-swallow LOS pressure of a 4-s period 
during which the LOS pressure was lowest, skipping 
periods of crural contractions if necessary. The upper limit 
of normal for the integrated relaxation pressure is 
10 mm Hg for type I achalasia, 15 mm Hg for type II 
achalasia, and 17 mm Hg for type III achalasia, which 
diﬀ erentiates best the impaired relaxation in achalasia 
from non-achalasic individuals and from patients with 
diﬀ use oesophageal spasm.56
Treatment
Pharmacological compounds
The two most often used pharmacological drugs are 
nitrates and calcium-channel blockers.57–60 Nitrates inhibit 
normal LOS contraction by dephosphorylation of the 
myosin light chain. In a Cochrane review, Wen and 
colleagues61 identiﬁ ed only two (poorly designed) 
randomised studies that assessed the clinical success of 
nitrates in achalasia and concluded that no solid recom-
mendations could be given. Nifedipine, in sublingual 
doses of 10–20 mg 15–60 min before meals, is the most 
widely used drug for achalasia. It inhibits LOS muscle 
contraction by blocking cellular calcium uptake and 
lowers the LOS resting pressure by 30–60%.57–59 However, 
a substantial drawback of its use is the occurrence of 
side-eﬀ ects such as hypotension, headache, and dizziness 
in up to 30% of patients.57–59 Moreover, drug tolerance 
develops with time.62
A more widely used pharmacological treatment is 
botulinum toxin A, a neurotoxin that blocks the release of 
acetylcholine from the nerve terminals. It is directly 
injected, at a dose of 80–100 units in four or eight 
quadrants, into the LOS through a sclerotherapy needle 
during upper-gastrointestinal endoscopy.63,64 Botulinum 
toxin is a safe and eﬀ ective treatment with few side-eﬀ ects. 
More than 80% of cases have a clinical response by 
1 month, but response fades rapidly, with less than 60% of 
patients in remission at 1 year.65 Findings from ﬁ ve 
Type I Type II Type III
Figure 3: Manometric types of achalasia 
Type I is characterised by absence of distal pressurisation to greater than 30 mm Hg. In type II, pressurisation to greater than 30 mm Hg occurs in at least two of 
ten test swallows, whereas patients with type III disease have spastic contractions with or without periods of compartmentalised pressurisation. Modiﬁ ed from 
Boeckxstaens and Zaninotto,54 with permission.
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randomised trials that compared botulinum toxin with 
pneumodilatation66–70 and one that compared botulinum 
toxin with laparoscopic myotomy71 showed initially com-
parable relief from dysphagia, but a rapid deterioration in 
patients treated with botulinum toxin after 6–12 months. 
Hence botulinum toxin, as is the case for nitrates and 
calcium-channel blockers, should be used only as an 
interim option before treatment with more durable 
treatments or in high-risk patients.
Pneumatic dilatation
Pneumatic dilatation, which tears the LOS by forceful 
stretching with air-ﬁ lled balloons, has become simpli-
ﬁ ed by the microinvasive Rigiﬂ ex balloon system 
(Boston Scientiﬁ c, Marlborough, MA, USA). These non-
compliant polyethylene balloons are available in three 
diameters (30, 35, and 40 mm), mounted on a ﬂ exible 
catheter placed over a guide wire at endoscopy. The 
general technique of pneumatic dilatation is summarised 
in the panel and ﬁ gure 4, although the actual protocol 
varies across centres.2 Under ﬂ uoroscopic guidance, the 
balloon is positioned across the LOS and gradually 
inﬂ ated until the waist is ﬂ attened. The most popular 
technique is a graded dilation protocol starting with a 
30 mm balloon.73 Subsequent dilations are spaced over 
2–4-week intervals on the basis of symptom relief 
associated with repeat LOS pressure measure ments39,74 or 
improvement in oesopha geal emptying.75,76 Pneumatic 
dilatation is usually done in an outpatient setting; the 
patient is observed for 2–6 h and can return to normal 
activities the next day. 
In a review of more than 1100 patients (24 studies) with 
an average follow-up of 37 months,77 Rigiﬂ ex pneumatic 
dilatation resulted in good to excellent symptom relief in 
74%, 86%, and 90% of patients treated with 30, 35, and 
40 mm balloons, respectively. Over 4–6 years, nearly a 
third of patients have symptom relapse;39,76,78 however, 
long-term remission can be achieved in nearly all these 
patients by repeat dilatation by an on-demand strategy on 
the basis of symptom recurrence.78 Patients with the best 
outcomes after pneumatic dilatation are those older than 
40 years, women, and those with a type II pattern by 
HRM.1,42,49,53,76,79 The most cost-eﬀ ective treatment for 
achalasia over a 5–10-year period after the procedure is 
pneumatic dilatation.80,81
Contraindications to pneumatic dilatation are poor 
cardiopulmonary status or other comorbid illnesses that 
would prevent surgery should an oesophageal perforation 
occur. Pneumatic dilatation can be done safely after a 
failed Heller myotomy, although larger diameter balloons 
are often needed.82 Up to 33% of patients have procedure-
related complications after pneumatic dilatation, but most 
are minor including chest pain, aspiration pneumonia, 
bleeding, transient fever, mucosal tear without perforation, 
and oesophageal haematoma. Oesophageal perforation is 
the most serious com plication, with an overall rate in 
experienced endoscopists of 2·0% (range 0–16%), of 
which 50% needed surgery.83 However, in a recent series 
of 16 transmural perforations, all cases were managed 
conservatively.84 Small per forations and painful deep tears 
can be treated with antibiotics and total parenteral 
nutrition for days to weeks.84 However, surgical repair by 
thoracotomy is best for large, symptomatic perforations 
with extensive soilage of the mediastinum. Most per-
forations occur during the initial dilatation; diﬃ  culty 
keeping the balloon in position is a potential risk factor.85 
Although no other predictors for perforation have been 
identiﬁ ed, a European achalasia trial reported more 
perfor ations, primarily in older patients, when the ﬁ rst 
pneumatic dilatation was done with a 35 mm compared 
with a 30 mm balloon.79 Complications of severe gastro-
oesophageal reﬂ ux disease are rare after pneumatic 
dilatation, but 15–35% of patients have heartburn, which 
improves with proton-pump inhibitors.77
Laparoscopic Heller myotomy 
Surgical myotomy of the muscle layer of the distal 
oesophagus and LOS, also known as Heller myotomy, 
is a time-honoured treatment for achalasia. It was ﬁ rst 
described in 1913 by the German surgeon, Ernst 
Heller,86 and has been widely used, with few technical 
changes, ever since. The two most important modi-
ﬁ cations to the original procedure are cutting of the 
cardia muscle ﬁ bres only on the anterior side87 and 
addition of a fundoplication to reduce the risk of gastro-
oesophageal reﬂ ux (ﬁ gure 5).90 
The advent of minimally invasive surgery has pro-
foundly changed the approach to Heller myotomy. 
Pellegrini and colleagues91 initially described a thoraco-
scopic approach for myotomy in 1992. However, laparo-
scopy oﬀ ers better visualisation of the distal oesophageal 
muscle layers and the sling ﬁ bres of the gastric fundus, 
Panel: General techniques for pneumatic dilatation with the Rigiﬂ ex balloon system2
• Patients are on a liquid diet for several days and fast for 12 h before endoscopy. Those 
with mega-oesophagus might need oesophageal lavage with a large-bore tube.
• The procedure is usually done as outpatient surgery in the morning.
• Upper endoscopy with conscious sedation in the left lateral position is done.
• Savary guide wire is placed in the stomach and a Rigiﬂ ex balloon is passed over it.
• The smallest balloon (30 mm) is usually used ﬁ rst. Beginning with a 35 mm balloon 
might be preferred in patients with previous pneumatic dilatation failures, young 
patients (<40 years), or after previous Heller myotomy.
• Accurate balloon placement is usually done with ﬂ uoroscopy (sometimes endoscopy). 
The key is careful location of the balloon so the waist caused by the non-relaxing lower 
oesophageal sphincter impinges on the middle portion of the distending balloon.
• The balloon is gradually distended until the waist is ﬂ attened. The pressure needed is 
usually 7–15 psi of air, held for 15–60 s. 
• The patient is repositioned in the left lateral position to minimise aspiration before the 
balloon is deﬂ ated and removed. 
• Post-procedure observation is done for 2–6 h to exclude perforation and assess for 
chest pain and fever. Patients with signiﬁ cant pain should be sent for a Gastrograﬁ n 
swallowing assessment to exclude oesophageal perforation.
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resulting in a shorter operation time and better results. 
In a recent review, Campos and colleagues92  showed that 
symptomatic improvement was signiﬁ cantly better with 
laparoscopic (n=3086 patients) than with thoracoscopic 
(n=211 patients) Heller myotomy (89·3% vs 77·6%, odds 
ratio 1·9, 95% CI 1·1–3·7; p=0·048) and reduced the 
incidence of postoperative gastro-oesophageal reﬂ ux 
(14·9% vs 28·3%, odds ratio 2·8, 95% CI 1·1–7·2; 
p=0·03). Because the antireﬂ ux barrier function of the 
LOS is lost after myotomy, the need to add an antireﬂ ux 
procedure (fundoplication) to Heller myotomy has been 
debated for many years. Findings from the meta-analysis 
by Campos and colleagues92 showed similar therapeutic 
success but a signiﬁ cant reduction of gastro-oesophageal 
reﬂ ux symptoms when a fundopli cation was added to 
Heller myotomy (31·5% vs 8·8%; p=0·001). Similar 
results were reported in a randomised controlled trial.93 
In view of the absence of peristalsis in achalasia, the 
type of fundoplication applied might have a major eﬀ ect 
on outcome. Postoperative dysphagia is higher after 
Nissen fundoplication than after partial anterior fun-
doplication (15·0% vs 2·8% p=0·001).93,94 Findings from 
a recent multicentre trial suggest that both anterior 
(Dor) and posterior (Toupet) partial fundoplication 
provide comparable control of reﬂ ux after laparoscopic 
Heller myotomy.95
Laparoscopic Heller myotomy combined with partial 
fundoplication is a safe operation with a reported 
mortality of 0·1% (three deaths in 3086 patients).92 The 
most common complication of laparoscopic Heller 
myotomy is perforation of the oesophageal or gastric 
mucosa during the myotomy, which is usually recognised 
during the procedure and repaired immediately without 
any consequences. The overall complication rate of 
laparoscopic Heller myotomy is 6·3% (range 0–35%), 
but clinical consequences are reported in only 0·7% 
(range 0–3%) of cases.96–105 The table summarises the 
outcome data of studies with 100 patients or more.96–105 In 
a systematic review, the mean success rate was 89% 
(range 76–100%) at a median follow-up of 35 months 
(range 8–38).92 However, success rates decrease 
(depending on the deﬁ nition used) to 65–85% at 5 years’ 
follow-up, probably because of disease progression.102,106,107
Positive prognostic factors after laparoscopic Heller 
myotomy are young age (<40 years), a LOS resting pressure 
greater than 30 mm Hg, and a straight oesophagus (ie, 
with no tortuosities at its distal end, as in sigmoid 
oesophagus).99,101 As for pneumodilatation, the manometric 
pattern at diagnosis also aﬀ ects clinical success rates after 
Heller myotomy—ie, patients with achalasia type II have 
the best outcome.108 Although no diﬀ erence in outcome 
between Heller myotomy and pneumodilatation has been 
noted for patients with type I and II achalasia, patients 
with type III disease seem to respond better to Heller 
myotomy than to pneumo dilatation,42 probably because 
myotomy entails a more extensive and more proximal 
disruption of the oesophageal muscle than does 
dilatation.108 The eﬀ ect of past endoscopic treatment on the 
outcome of laparoscopic  Heller myotomy is controversial: 
ﬁ ndings from some studies102–104 suggested that multiple 
endoscopic treat ments could hamper the results of sur-
gery, whereas Portale and colleagues109 reported that only 
patients previously treated with both botulinum toxin 
injection and pneumodilation had a less favourable out-
come than did those who had not had such procedures 
previously. However, to what extent these patients are less 
responsive to any treatment remains unclear. 
Balloon 
completely inflated
Guide wire
Balloon inserted and 
inflated, expanding LOS
Pneumatic
dilator
Oesophageal
dilatation
LOS
Restored 
flow complete
Stomach
Figure 4: Pneumatic dilatation with the Rigiﬂ ex system
Schematic representation of the pneumodilatation procedure. The deﬂ ated balloon is inserted over a guide wire, 
after which the slightly inﬂ ated balloon is positioned at the oesophagogastric junction with the indentation still 
visible. Finally, the balloon is fully inﬂ ated and the indentation disappears. After removal of the balloon, the LOS is 
distended, allowing adequate passage. LOS=lower oesophageal splinter. Reproduced from Johns Hopkins 
Medicine, Gastroenterology and Hepatology.72  Illustration Copyright ©1998–2003 by The Johns Hopkins Health 
System Corporation; used with permission www.hopkins-gi.org. Illustration created by Mike Linkinhoker.  
Figure 5: Schematic representation of laparoscopic Heller myotomy with Dor fundoplication (left) and 
per-oral endoscopic myotomy (right)
Left panels show the dissection of the muscle layer (top) and the creation of the Dor fundoplication (bottom). The 
right panel shows the endoscope positioned in the tunnel created between the muscle layer and mucosa, allowing 
endoscopic myotomy of the circular muscle layer. Reproduced from Zaninotto and Costantini88 and Inoue and 
colleagues,89 respectively, with permission.
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Recurrence of dysphagia most often develops within 
12–18 months after surgery.100,110 Incomplete myotomy, 
especially on the gastric side (where the myotomy is 
more diﬃ  cult), late scarring of the myotomy, and an 
excessively tight anti-reﬂ ux wrap are possible causes of 
treatment failure.110 As mentioned earlier, chest pain is 
more diﬃ  cult to treat than the other symptoms and 
patients should be informed about this issue.40 Recurrent 
symptoms after Heller myotomy can be safely treated 
with pneumo dilatation or, if such conser vative treatment 
fails, by repeat laparoscopic Heller myotomy.110
Pneumatic dilatation versus laparoscopic Heller myotomy
Until recently, addressing the question of whether to 
undertake pneumatic dilatation or laparoscopic Heller 
myotomy was diﬃ  cult because large prospective, 
randomised comparative studies were not available. In a 
review of case series from 1989 to 2006, Campos and 
colleagues92 reported an overall 68% improvement rate in 
1065 patients undergoing pneumatic dilatation with 
Rigiﬂ ex balloons whereas laparoscopic myotomy had an 
89% improvement rate in 3086 patients. In a study from 
the Cleveland Clinic (Cleveland, OH, USA),76 106 patients 
were treated with pneumatic dilatation and 73 patients 
underwent laparoscopic myotomy. Success, deﬁ ned as 
dysphagia or regurgitation fewer than three times per 
week or freedom from alternative treatments, was similar 
between groups: 96% for dilatation versus 98% for 
surgery at 6 months, decreasing to 44% versus 57% at 
6 years. A large retrospective longitudinal study from 
Ontario, Canada,111 provides the best estimate of long-
term outcomes with the procedures in typical practice 
settings. From 1991 to 2002, 1461 adults were treated for 
achalasia; 81% had pneumatic dilatation and 19% had 
surgical myotomy as their ﬁ rst procedure. The cumula-
tive risk of any subsequent treatment (dilatation, 
myotomy, or oesophagectomy) after 1, 5, and 10 years was 
36·8%, 56·2%, and 63·5% after initial pneumatic 
dilatation versus 16·4%, 30·3%, and 37·5% after initial 
myotomy (hazard ratio 2·37; 95% CI 1·86–3·02). This 
risk diﬀ erence occurred only when repeat pneumatic 
dilatation was recorded as an adverse event. 
In 2011, a prospective randomised comparative study 
was published that compared pneumatic dilatation and 
laparoscopic myotomy undertaken by physicians highly 
skilled in both procedures.79 In the European Achalasia 
Trial,79 patients from ﬁ ve countries were randomly assigned 
to Rigiﬂ ex dilatation (n=94; 30 and 35 mm with up to three 
repeat dilations allowed) or laparoscopic myotomy with 
Dor fundoplication (n=106). Both treat ments had com-
parable success in relieving symptoms at 2 years: 86% for 
dilatation and 90% for myotomy. Barium emptying and 
LOS pressure were both improved to similar extents in 
both groups. However, the follow-up was short (at least 
2 years) and retreatment was allowed. Pre-existing daily 
chest pain, oesophageal width less than 4 cm before 
treatment, and post-treatment poor oesophageal emptying 
with barium column greater than 10 cm were identiﬁ ed as 
predictors of treatment failure. Although not a predictor of 
clinical success for either treatment, patients younger than 
40 years more often needed repeat pneumatic dilatations 
than did those older than 40 years.
Per-oral endoscopic myotomy
Per-oral endoscopic myotomy (POEM) is a recently 
developed endoscopic technique for treatment of 
achalasia.89 In brief, the endoscopist creates a submucosal 
tunnel to reach the LOS and to dissect the circular muscle 
ﬁ bres over a 7 cm oesophageal and 2 cm gastric length 
(ﬁ gure 5). Inoue and colleagues89 reported a success rate 
of 100% and a signiﬁ cant reduction in LOS pressure 
in 17 patients. Subsequent studies of 11–18 patients 
conﬁ rmed the high success rate (89–100%), even after 
several previous pneumatic dilatations.112–116 However, 
physiological data are limited and follow-up was short 
(mean 6 months). Moreover, especially because no 
antireﬂ ux procedure is included in this technique, the 
risk of gastro-oesophageal reﬂ ux is substantial (up to 
46% in one study113) and might represent an important 
drawback. Longer follow-up is needed and randomised 
studies to compare POEM with pneumatic dilatation or 
laparoscopic Heller myotomy should be done before 
accepting POEM as new treatment option for achalasia.
Oesophagectomy for end-stage achalasia
Despite the eﬃ  cacy of pneumodilatation and laparo-
scopic Heller myotomy, 2–5% of patients will develop 
end-stage disease,117 deﬁ ned as a massive dilatation of 
the oesophagus with retention of food, unresponsive 
reﬂ ux disease, or the presence of preneoplastic lesions.48 
In these cases, oesophageal resection might be 
necessary to improve the patient’s quality of life and 
avoid the risk of invasive carcinoma. The risk of 
needing oesophagectomy is higher if the oesophagus is 
already markedly dilated at the ﬁ rst intervention than if 
it is mildly dilated (<4 cm).118
Number of patients Follow-up (months) Patients in remission (%) 
Oelschlager et al (2003)96 110 46 100 (91%)
Perrone et al (2004)97 100 26 92 (92%)
Rossetti et al (2005)98 195 83 179 (92%)
Torquati et al (2006)99 200 43 170 (85%)
Schuchert et al (2008)100 194 32 180 (93%)
Zaninotto et al (2008)101 400 30 348 (87%)
Snyder et al (2009)102 134 22 115 (86%)
Finley et al (2010)103 261 36 181 (69%)
Rosemurgy et al (2010)104 505 31 404 (80%)
Carter et al (2011)105 165 62 125 (76%)
Total 2264 42* 84%
*Mean.
Table: Remission of symptoms after laparoscopic myotomy in series of 100 or more patients 
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The ideal reconstruction method after oesophagectomy 
has not yet been established. Gastric interposition has 
the advantage of needing only one anastomosis, but 
gastro-oesophageal reﬂ ux can cause severe damage if 
the anastomosis is intrathoracic. If a total oesopha-
gectomy is done and the anastomosis is in the neck, the 
critical vascular supply to the gastric tube can be 
compromised, resulting in anastomotic leakage and 
stricture.48 Alternatively, a long colonic interposition can 
be constructed, but anastomotic failure or stricture due 
to ischaemia might occur. Short-segment colon inter-
position with an intrathoracic anastomosis might be a 
valid option in such patients.48 In a recent review that 
included 295 patients,119 an optimum outcome (deﬁ ned 
as unrestricted or regular diet) was present in 65–100% 
of patients at a medium follow-up of 44 months 
(range 25–72), irrespective of the technique used.
Risk factors and therapeutic guidelines 
Standardisation of balloon systems and development of 
laparoscopic myotomy and, most recently, HRM has 
helped better deﬁ ne the types of patient who will respond 
well to pneumatic dilatation versus laparoscopic 
myotomy. These predictors are age, sex, and manometric 
type by HRM. The favourable eﬀ ects of older age 
(>40 years) on the success of pneumatic dilatation are the 
most reproducible, from as far back as 1971.1,74,76,79 Findings 
from several studies suggest that young men respond 
less well than do women to pneumatic dilatation.76,120 For 
example, in a study at the Cleveland Clinic (106 patients, 
51 women),76 men up to age 50 years had poor outcomes 
after a 30 mm Rigiﬂ ex pneumatic dilatation. However, 
young women (<35 years) also did not respond well, 
whereas most women aged 35 years or older had 
sustained relief over at least 5 years after a pneumatic 
dilatation. Although not well studied, this ﬁ nding is 
probably a result of stronger LOS tone in young patients, 
especially men.121 Pandolﬁ no and colleagues53 reported 
that HRM patterns in achalasia predicted treatment 
success, especially after pneumatic dilatation. Success 
rates were signiﬁ cantly higher for type II achalasia 
(96%) than for type I (56%) and type III (29%) achalasia. 
These ﬁ ndings were supported by the prospective 
European Achalasia Trial, which reporting that type III 
disease might be best treated by laparoscopic myotomy.42
Identiﬁ cation of predictors of success can guide our 
recommendation for treatment of achalasia (ﬁ gure 6).2 
Healthy patients with achalasia should be given the option 
of graded pneumatic dilatation or myotomy. Myotomy will 
be the more eﬀ ective treatment in adolescents and 
younger adults, especially men and possibly patients with 
type III achalasia. Myotomy is also the treatment of choice 
in uncooperative patients and those in whom pseudo-
achalasia cannot be excluded. Women and patients older 
than 40–50 years can expect good outcomes with either 
pneumatic dilatation or myotomy. Botulinum toxin 
injection should be the ﬁ rst-line treatment for elderly 
patients or those with severe comorbid illnesses because it 
is safe, improves symptoms, and might need retreatment 
no more than yearly. However, pneumatic dilatation is a 
reasonable alternative in high-risk patients if done in 
high-volume (ie, experienced) centres with surgical 
expertise, should the rare perforation occur. The role of 
POEM as a substitute for myotomy will be deﬁ ned in time 
once there has been longer term follow-up of symptoms 
and physiological studies.
Long-term management
To screen or not to screen for dysplasia? 
As a result of functional obstruction, large amounts of 
food and saliva can be retained within the oesophagus, 
especially if treatment is suboptimal. Increased bacterial 
growth and chemical irritation from the con tinuous 
decomposition of food and saliva can induce chronic 
hyperplastic oesophagitis, dysplasia, and eventually 
malignant transformation of oesophageal epithelial cells.122 
The risk of oesophageal carcinoma varies substantially, 
ranging from ten to 50 times in patients with achalasia 
compared with the general population.43 ,123–129 In a large 
long-term prospective trial, a hazard ratio of 28 was 
reported for development of oesophageal squamous-cell 
carcinoma in patients with achalasia compared with 
matched control individuals.129
Because one of the main symptoms of oesophageal 
carcinoma, dysphagia, is frequently attributed to exacer-
bation or recurrence of achalasia, diagnosis of oesophageal 
carcinoma is often delayed, explaining the poor prognosis 
in achalasia.130 This situation raises the question of whether 
an endoscopic surveillance pro gramme should be initiated 
for early detection of cancer. However, so far no consensus 
Low surgical risk
Manometric
type III disease
Age <40 years
Failure
Failure
Failure
Failure
Success
Age >40 years
High surgical risk
Laparoscopic 
myotomy
Refer to oesophageal centre of 
excellence
Refer to oesophageal centre of 
excellence 
Graded pneumatic 
dilatation
Graded pneumatic 
dilatation
Botulinum toxin
Repeat as needed Success
Repeat as needed
Repeat myotomy
Oesophagectomy
Calcium-channel 
blocker or nitrates
Pneumatic 
dilatation
Figure 6: Proposed therapeutic algorithm for achalasia
Modiﬁ ed from Richter and Boeckxstaens.2
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on this topic has been reached for several reasons.131 First, 
the death rate from oesophageal cancer diagnosed during 
a surveillance programme is not diﬀ erent from that of the 
normal population.129 Second, endoscopic surveillance is 
diﬃ  cult in patients with achalasia because the whole 
segment is at risk, the mucosa is often covered with food 
debris and has a cobblestone appearance, and random 
biopsies might not be representative. Third, the cost-
eﬀ ectiveness of a surveillance programme is dubious 
because the incidence of cancer is low. However, screening 
programmes under taken so far used standard white light 
endoscopy.43,123–129 With the introduction of high-resolution 
endoscopy and chromoendoscopy with Lugol’s staining, 
the sensitivity to detect premalignant lesions has signiﬁ -
cantly improved.132 In a recent study, Lugol’s staining 
detected more dysplastic lesions than did white light 
endoscopy in patients with longstanding achalasia.133 These 
lesions were detected in patients diagnosed with achalasia 
for more than 20 years. Hence, a possible screening 
strategy could be to start an endoscopic surveillance 
programme 10 years after initial treatment using Lugol’s 
staining,133 particularly in high-risk patients (ie, men);128,134 
however, more studies are needed. An additional (but 
costly) strategy might be to use biomarkers such as p53, 
which precede the appearance of oesophageal carcinoma 
in patients with achalasia by several years.135
How to predict need for retreatment 
Nearly 90% of patients with achalasia can return to near 
normal swallowing and good quality of life with present 
treatments.136 However, few are cured with one treatment, 
many relapse over time, and intermittent top-up pro-
cedures might be needed. How can we predict which 
patients will need re-treatment? Physiological studies are 
the best predictors of long-term success of treatment. 
Eckardt and colleagues74 reported that all patients with a 
post-procedure LOS pressure less than 10 mm Hg were 
in remission after 2 years, 71% were in remission for 
pressures between 10 and 20 mm Hg, and 23% for 
pressures over 20 mm Hg. More recently, Hulselmans 
and colleagues39 noted that 66% of patients with post-
procedure LOS pressure less than 15 mm Hg were in 
symptomatic remission after 6 years. 
The timed barium oesophagram assesses upright 
oesophageal emptying over 5 min, is readily available, is 
non-invasive,50 and is a better predictor of success than 
is LOS pressure if there is good oesophageal emptying 
even if LOS pressure was below 10 mm Hg.75 Vaezi and 
colleagues49 reported that patients with complete 
symptom relief associated with marked improvement in 
oesophageal emptying were more likely to do well at 
3 years than those with symptom relief but poor 
oesophageal emptying (82% vs 10%, respectively). This 
ﬁ nding was conﬁ rmed in the prospective European 
Achalasia Trial79 and was shown in a subsequent analysis 
to be more predictive of success than post-treatment 
LOS pressure, with a sensitivity of 88% versus 20%.75 
More recently, these investigators used the new Endoﬂ ip 
system (MMS, Enschede, Netherlands), which measures 
the distensibility of the oesophagogastric junction with 
a balloon catheter passed across the LOS, to measure 
the cross-sectional area of the sphincter using 
impedance planimetry.137,138 In patients with achalasia, 
oesophago gastric junction distensibility was associated 
with oesophageal emptying by barium and a low total 
symptom score and was signiﬁ cantly increased with 
treatment. Patients with normal oesopha gogastric 
junction distensibility (>2·9 mm²/mm Hg) usually had 
complete upright oesophageal emptying by 5 min, 
whereas those with persistent impaired distensibility 
had a mean barium column height of 5–8 cm at 5 min.137
On the basis of these data, we believe that all patients, 
irrespective of treatment or symptoms, need physiological 
follow-up of their achalasia. Assessment of symptoms and 
an upright time barium oesophagram done 1–3 months 
after treatment seems a practical approach. Those with 
symptom relief and good oesophageal emptying will do 
well long term and should be followed up on a regular 
basis (ie, every 2–3 years). Those with persistent 
symptoms, poor oesophageal emptying, or both warrant 
further treatment or close follow-up at 1 year.
Future treatment
Present approaches used to treat achalasia destroy the 
LOS rather than try to correct the underlying abnor-
mality and to restore function. Assuming that the 
disappearance of myenteric neurons results from an 
immune-mediated process, one could theoretically 
consider immune modu latory drugs. However, at the 
time of diagnosis the number of neurons has already 
decreased to a critical level, questioning whether 
arresting the inﬂ ammatory process will restore function. 
However, a recent case report of a patient with achalasia 
and eosinophilic oesophagitis showed improved 
oesophageal motility and disappearance of dysphagia 
after treatment with 50 mg prednisolone.139
An alternative possible treatment option is trans-
plantation of neural stem cells. Recent advances in 
stem-cell research will hopefully shift treatment 
towards functional recovery.140 In particular, the 
discovery that neural stem cells (or so-called neuro-
spheres) can be isolated and cultured from mucosal 
biopsies141 will undoubtedly provide new options for 
treatment of aganglionic gastrointestinal diseases, 
including achalasia. Metzger and colleagues141 generated 
neurosphere-like bodies from mucosal biopsies capable 
of proliferating and generating multiple neuronal 
subtypes. On transplantation, neuro sphere-like bodies 
colonised cultured aganglionic human hindgut to 
generate ganglia-like structures and enteric neurons 
and glia. Comparable ﬁ ndings were reported by another 
group;142,143 however, after trans plantation in vivo into 
the mouse pylorus, the grafted neurosphere-like bodies 
failed to adopt a neuronal phenotype.142 More research 
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is needed to optimise the technique of stem-cell 
transplantation before achalasia can really be cured, but 
there is deﬁ nitely light at the end of the tunnel.
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